Impact of Levosimendan treatment on chronic heart failure

被引：3

作者：

von Haehling, S

Diller, GP

Anker, SD

机构：

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 08期

关键词：

D O I：

10.1016/j.amjcard.2004.05.078

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1105 / 1105

页数：1

共 6 条

[1] Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].

Anker, SD ;

Negassa, A ;

Coats, AJS ;

Afzal, R ;

Poole-Wilson, PA ;

Cohn, JN ;

Yusuf, S .

LANCET, 2003, 361 (9363) :1077-1083

[2]

Cleland John G F, 2004, Expert Rev Cardiovasc Ther, V2, P9, DOI 10.1586/14779072.2.1.9

[3] Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals [J].

Odaka, C ;

Mizuochi, T .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 121 (03) :515-522

[4] Anemia in chronic heart failure: Pathogenetic mechanisms [J].

Okonko, DO ;

Anker, SD .

JOURNAL OF CARDIAC FAILURE, 2004, 10 (01) :S5-S9

[5] Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure [J].

Parissis, JT ;

Adamopoulos, S ;

Antoniades, C ;

Kostakis, G ;

Rigas, A ;

Kyrzopoulos, S ;

Iliodromitis, E ;

Kremastinos, D .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (10) :1309-1312

[6] Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway [J].

Romeo, F ;

Li, DY ;

Shi, M ;

Mehta, JL .

CARDIOVASCULAR RESEARCH, 2000, 45 (03) :788-794

← 1 →